Goldman Sachs Price Target Update: Goldman Sachs raised its price target on TGT Therapeutics to $39 from $37 while maintaining a 'neutral' rating, indicating a potential upside of over 32% from the last close.
Briumvi's Market Presence: TGT Therapeutics' CEO announced that Briumvi is now available in 16 countries, with over 20,000 patients prescribed the drug, primarily in the United States.
Revenue Expectations: TGT Therapeutics anticipates U.S. revenue from Briumvi to be between $825 million and $850 million, which would significantly contribute to the company's total revenue.
Retail Sentiment Improvement: Retail sentiment towards TGT Therapeutics has improved to 'extremely bullish,' with a notable increase in message volume and a 69% spike in followers on the platform in the last week.
Wall Street analysts forecast XLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLV is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast XLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLV is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 158.260
Low
Averages
High
Current: 158.260
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
